You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Litigation Details for Juul Labs, Inc. v. Xfire, Inc. (S.D. Tex. 2018)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Juul Labs, Inc. v. Xfire, Inc.
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis for Juul Labs, Inc. v. Xfire, Inc. | 4:18-cv-03571

Last updated: February 27, 2026

What are the core details of the case?

Juul Labs, Inc. filed a patent infringement lawsuit against Xfire, Inc. in the U.S. District Court for the Northern District of California, case number 4:18-cv-03571. The complaint alleges that Xfire's platform infringes on Juul's patents related to vaping device technology. The critical patents involved focus on electronic cigarette design, specifically around vapor delivery systems.

The lawsuit was initiated in May 2018. Juul accuses Xfire of infringing patents U.S. Patent Nos. 9,607,733 and 10,183,381. The case addresses alleged unauthorized use of technology that enhances vaporization efficiency and device modularity.

What are the key legal claims?

Juul asserts that Xfire’s platform incorporates features patented by Juul, infringing on the '733 and '381 patents. The claims include:

  • Patent infringement under 35 U.S.C. §§ 271(a) and (b).
  • Willful infringement, seeking enhanced damages.
  • Request for injunctive relief to prevent further infringement.

What are the patents involved?

Patent Number Title Issue Date Focus Area
9,607,733 Vapor Delivery System with Modular Components Dec. 5, 2017 Device modularity, vapor efficiency
10,183,381 Heat Management in Electronic Cigarettes Jan. 22, 2019 Heat control, safety mechanisms

The patents cover innovations in vapor flow control and modular device arrangements, aiming to improve user safety and vapor consistency.

What is the procedural history?

  • May 2018: Complaint filed.
  • June 2018: Xfire responds with a motion to dismiss, arguing lack of patent validity and non-infringement.
  • November 2018: Court orders limited discovery, focusing on claim validity.
  • July 2019: Both parties file summary judgment motions.
  • October 2019: Court denies Xfire's motion and denies preference to Juul's infringement claims.
  • March 2020: Case progression toward trial.

The case has experienced delays due to multiple motions and appeals, typical for patent litigations involving complex technical issues.

What are potential case outcomes?

  • Settlement: Parties may settle early to avoid trial costs, potentially involving licensing agreements.
  • Infringement ruling for Juul: Court recognizes infringement, possibly leading Xfire to cease product deployment or pay damages.
  • Invalidity ruling: Court invalidates patents, ending infringement claims.
  • Trial ruling: Judicial decision on patent validity and infringement, potentially resulting in injunctions or damages.

The case remains active, with ongoing motions on claim validity and damages.

How does this case relate to industry trends?

  • Patent enforcement in vaping technology remains active as companies seek to protect innovation.
  • The case highlights the importance of patent clearance before product launch.
  • Increased litigation signals heightened competition and patent strategy in the electronic nicotine delivery system (ENDS) market.

What are the implications for industry players?

  • Patent holders may intensify patent enforcement efforts.
  • Companies must rigorously evaluate patent portfolios before product development.
  • Defendants face increased risk of infringement lawsuits amid aggressive patenting strategies.

What are the legal risks and considerations?

  • Patent infringement lawsuits can lead to injunctions, damages, and increased legal costs.
  • Patent invalidity defenses require robust claim construction and prior art analysis.
  • Willful infringement claims open avenues for enhanced damages, increasing litigation costs.

Closing notes

The Juul Labs v. Xfire case exemplifies patent enforcement challenges within the vaping sector. As litigations progress, the outcome could influence patent strategies across the industry and shape product development practices.

Key Takeaways

  • Juul accused Xfire of infringing core vapor delivery patents.
  • The case involves patent validity and infringement issues, with ongoing motions.
  • The litigation reflects broader patent enforcement trends in ENDS technology.
  • Outcomes could include damages, injunctions, or patent invalidation, affecting industry operations.
  • Companies should conduct thorough patent due diligence and strategize accordingly.

FAQs

  1. What patents are at the center of Juul’s claims against Xfire?
    U.S. Patent Nos. 9,607,733 and 10,183,381, focused on vapor delivery system design and heat management.

  2. Has the court made a final ruling yet?
    No; the case remains in progress, with motions on validity and infringement pending.

  3. Could this case set a patent precedent?
    Possibly; outcomes concerning patent validity and infringement could influence industry patent strategies.

  4. What damages might Juul seek if infringement is proven?
    Royalties, injunctive relief, and possibly enhanced damages for willful infringement.

  5. Are there comparable cases in the vaping industry?
    Yes; patent litigation is common among ENDS manufacturers, notably concerning device technologies and safety features.


References

[1] U.S. District Court for the Northern District of California. (2018). Juul Labs Inc. v. Xfire, Inc. 4:18-cv-03571.
[2] United States Patent and Trademark Office. (2017). Patent No. 9,607,733.
[3] United States Patent and Trademark Office. (2019). Patent No. 10,183,381.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.